Minnesota Oncology

Brain Cancer News

Follow-Up Study Shows ICT-107 Vaccine Fails to Extend Survival in GBM (January 27, 2014)

Despite promising results in a phase I trial, the vaccine ICT-107 failed to significantly prolong overall survival in patients with glioblastoma multiforme in a follow-up phase II trial.[1] Glioblastoma multiforme (GBM) is an aggressive type of type of... Continue Reading

Novel Vaccine Prolongs Survival in Glioblastoma Multiforme (December 20, 2013)

Eight of 16 patients with glioblastoma multiforme who participated in a vaccine study survived longer than fiver years after diagnosis, according to the results of a study presented at the Fourth Quadrennial Meeting of the World Federation of Neuro-Oncology. Glioblastoma... Continue Reading

No Added Toxicity with Avastin in Glioblastoma (October 9, 2013)

The addition of Avastin® (bevacizumab) to standard chemoradiation significantly slowed the progression of glioblastoma without added toxicity, according to the results of a study presented at the annual meeting of the American Society of Radiation Oncology. Glioblastoma... Continue Reading

Antiviral Drug May Extend Survival in Glioblastoma (September 25, 2013)

The common antiviral drug Valcyte (valganciclovir) may extend survival in glioblastoma, according to the results of a study published in the New England Journal of Medicine. Glioblastoma is one of the most common and fatal types of primary brain cancer.... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Avastin Doesn’t Improve Survival in Newly Diagnosed Glioblastoma (June 7, 2013)

In a Phase III clinical trial among patients with newly diagnosed glioblastoma, the addition of Avastin® (bevacizumab) to standard chemoradiation increased side effects and did not improve overall survival. These results were presented at the 2013 Annual... Continue Reading

Agenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine With Avastin in Treatment of Brain Tumors (May 22, 2013)

Study Seeking to Enroll 222 Patients; Largest Vaccine Trial Ever Funded by NCI in Brain Tumors and the Largest Cancer Vaccine Study Ever Conducted in Combination With Avastin LEXINGTON, Mass., May 22, 2013 (GLOBE NEWSWIRE) — Agenus Inc. (Nasdaq:AGEN)... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

Early Resection of Low-Grade Gliomas Improves Survival (November 21, 2012)

Patients in Norway with low-grade gliomas who were treated with early surgical resection had better overall survival than those treated with biopsy and watchful waiting, according to the results of a study published in the Journal of the American Medical... Continue Reading

Latest Brain Cancer News By Stage


General Brain Cancer

Follow-Up Study Shows ICT-107 Vaccine Fails to Extend Survival in GBM (January 27, 2014)

Despite promising results in a phase I trial, the vaccine ICT-107 failed to significantly prolong overall survival in patients with glioblastoma multiforme in a follow-up phase II trial.[1] Glioblastoma multiforme (GBM) is an aggressive type of type of... Continue Reading

Novel Vaccine Prolongs Survival in Glioblastoma Multiforme (December 20, 2013)

Eight of 16 patients with glioblastoma multiforme who participated in a vaccine study survived longer than fiver years after diagnosis, according to the results of a study presented at the Fourth Quadrennial Meeting of the World Federation of Neuro-Oncology. Glioblastoma... Continue Reading

No Added Toxicity with Avastin in Glioblastoma (October 9, 2013)

The addition of Avastin® (bevacizumab) to standard chemoradiation significantly slowed the progression of glioblastoma without added toxicity, according to the results of a study presented at the annual meeting of the American Society of Radiation Oncology. Glioblastoma... Continue Reading

Antiviral Drug May Extend Survival in Glioblastoma (September 25, 2013)

The common antiviral drug Valcyte (valganciclovir) may extend survival in glioblastoma, according to the results of a study published in the New England Journal of Medicine. Glioblastoma is one of the most common and fatal types of primary brain cancer.... Continue Reading

Avastin Doesn’t Improve Survival in Newly Diagnosed Glioblastoma (June 7, 2013)

In a Phase III clinical trial among patients with newly diagnosed glioblastoma, the addition of Avastin® (bevacizumab) to standard chemoradiation increased side effects and did not improve overall survival. These results were presented at the 2013 Annual... Continue Reading

More General Brain Cancer